Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020)

Grifols (GRFS) reported Net Income towards Common Stockholders of $330.1 million for Q1 2020, up 69.41% on a YoY basis from $194.8 million in Q2 2019, and down 55.46% quarter-over-quarter from $741.2 million in Q4 2019.

Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020) Analysis & Trends

Grifols has reported Net Income towards Common Stockholders for 10 years, with the latest figure at $330.1 million in Q1 2020.

  • For the quarter ending Q1 2020, Net Income towards Common Stockholders rose 69.41% year-over-year to $330.1 million; the trailing twelve-month figure through Dec 2021 stood at $330.1 million (down 69.19% YoY), and the FY2025 full-year result was $467.9 million, up 178.92% from the prior year.
  • Net Income towards Common Stockholders for Q1 2020 stood at $330.1 million, down from $741.2 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $882.3 million in Q4 2017, with the low at $150.5 million in Q4 2016.
  • Historically, Net Income towards Common Stockholders has averaged $389.3 million across 5 years, with a median of $264.1 million in 2018.
  • Annual changes were most pronounced in 2016 — Net Income towards Common Stockholders soared 137874.31% — and 2019, when it retreated 26.23%.
  • Grifols' Net Income towards Common Stockholders stood at $150.5 million in 2016, then surged by 486.37% to $882.3 million in 2017, then declined by 9.06% to $802.4 million in 2018, then fell by 7.63% to $741.2 million in 2019, then slumped by 55.46% to $330.1 million in 2020.
  • The last three Net Income towards Common Stockholders figures came in at $330.1 million (Q1 2020), $741.2 million (Q4 2019), and $194.8 million (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.34 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -13.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Grifols 6.05 Bn 5.09 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2020 330.09 Mn
Dec 31, 2019 741.18 Mn
Mar 31, 2019 194.84 Mn
Dec 31, 2018 802.38 Mn
Jun 30, 2018 209.54 Mn
Mar 31, 2018 264.14 Mn
Dec 31, 2017 882.31 Mn
Jun 30, 2017 255.10 Mn
Mar 31, 2017 247.88 Mn
Dec 31, 2016 150.47 Mn
Sep 30, 2016 453.28 Mn
Jun 30, 2016 202.82 Mn
Mar 31, 2016 327.20 Mn
Dec 31, 2015 143.08 Mn
Sep 30, 2015 155.84 Mn
Jun 30, 2015 147,000.37
Mar 31, 2015 145.17 Mn
Sep 30, 2013 111.62 Mn
Jun 30, 2013 119.87 Mn
Mar 31, 2013 120.15 Mn